We count visits as totals without cookies, and never follow you from one day to the next. If you accept, we also use cookies to see how people use this site, so we can improve it. Privacy policy
Last close (USD)549.04+18.28 (+3.44%)as of 4 Nov 2026
Funds that hold it13One fund per scheme
Held through a master fund130 buy the stock themselves
Largest weight in a single fund4.83%Of that fund's NAV
Median weight2.58%Half the funds hold more than this
What does VRTX do
Vertex Pharmaceuticals Incorporated
Develops and sells drugs mainly for cystic fibrosis (an inherited lung disease), and is expanding into pain treatments and gene therapy. Almost all revenue comes from prescription drug sales
Where the revenue comes from, and how much is left as profit (FY2025)
For every 100 dollars of sales: cost of sales 14 · operating expenses 51 · other items 0 · tax and other items 2 · leaving 33 as net profit
Which funds let you invest in VRTX
Sorted by weight held, largest first
Investors in Thailand can buy VRTX through 13 mutual funds open to retail investors. Most of them (13 funds) don't buy the stock themselves. Instead they invest in a master fund abroad, which in turn holds VRTX.
The many funds holding less than 3% are usually index funds holding at market weight · Funds holding more than 8% have deliberately chosen a large position
How many funds each AMC holds it through
UOBAM
How Thai money reaches VRTX
8 master funds
Master fund
Thai funds using this route
Master fund's VRTX weight
United Global Healthcare Fund
3
2.61%
Wellington Global Health Care Equity Fund
3
2.29%
Capital Group New Economy Fund (LUX) – Class Z (USD)
2
1.79%
BNP Paribas Funds Health Care Innovators
1
4.83%
Data sourcesFunds that buy the stock themselves: top 5 holdings from the AMC's fact sheet as of 30 Sep 2026 · Funds that invest through a master fund: the master fund's portfolio from its issuer's fact sheet or prospectus · Each scheme counts as one fund · Share price: Market data · Financial statements: SEC EDGAR · Ratios: Market data · Revenue by business segment: SEC EDGAR · Weights are as of the report date, and funds can change their portfolios at any time · Investing involves risk. This is not investment advice.
Showing 10 of 13 funds you can buy · The full list is in the Expert view · Latest weights from portfolio reports, and funds can change their portfolios at any time · Past performance is not a guarantee of future performance
Vertex Pharmaceuticals Incorporated · NASDAQ · Fiscal year ends in January
Market cap138.9B USD0.25 billion shares
P/E35.8xPrice ÷ FY2025 EPS 15.32
Forward P/E26.0xBased on forecast 12-month earnings
P/S10.8x
EV/EBITDA27.6x
Dividend yield0.00%0.00 USD per share a year
ROE22.5%Net profit ÷ shareholders' equity
Debt to equity (D/E)0.00xInterest-bearing debt
Beta0.29Against the S&P 500
Gross margin86.2%FY2025
Operating margin34.8%FY2025
Net margin32.9%FY2025
Price ratios use the latest close shown on this page · Forward P/E, P/S and EV/EBITDA from Market data · Beta from 5 years of monthly returns · Total dividends over the last 12 months
Company health made simple
From the FY2025 statements
Sales growth12.2%Fast growth
Yearly average over the last 4 years · Latest annual sales 12.0B USD
Profit from sales33%Highly profitable
For every 100 dollars of sales, about 33 dollars is left as net profit
Dividend0.00%No dividend
Per year, relative to the share price · Tech stocks tend to pay little because they reinvest their profits
1-year share price+30.2%Up
Now 1.8% below its 1-year high
A rise or fall in the share price doesn't move a fund by the same amount — a fund is affected only in proportion to how much it holds
Financial statements
Revenue grows 12.2% a year on average · EPS grows 14.2% a year on average
Annual · last 5 fiscal years
Revenue and net profit
FY20217.6B USD2.3B USD
FY20228.9B USD3.3B USD
FY20239.9B USD3.6B USD
FY202411.0B USD−536.0M USD
FY202512.0B USD4.0B USD
Total revenue
Net profit
Quarterly · last 5 quarters
Revenue and net profit
Q2 FY20253.0B USD1.0B USD
Q3 FY20253.1B USD1.1B USD
Q4 FY20253.2B USD1.2B USD
Q1 FY20263.0B USD1.0B USD
Q2 FY20263.3B USD1.1B USD
Annual income statement, balance sheet and cash flow
Item (USD)
FY2021
FY2022
FY2023
FY2024
FY2025
Total revenue
7.6B USD
8.9B USD
9.9B USD
11.0B USD
12.0B USD
Gross profit
6.7B USD
7.9B USD
8.6B USD
9.5B USD
10.4B USD
Operating profit
Free cash flow = operating cash flow − capital expenditure · A cell showing N/A is an item the statement doesn't report, not a zero · Source: SEC EDGAR
Technical analysis
Closed at 549.04 USD on 4 Nov 2026
Daily trendClear uptrendScore 1.00 on a scale of −1 to +1 · 1253 bars
RSI(14)
59.3
ADX(14)
24.0
Position in the price range
87%
Weekly trendClear uptrendScore 1.00 on a scale of −1 to +1 · 261 bars
RSI(14)
61.2
ADX(14)
28.0
Position in the price range
93%
Monthly trendClear uptrendScore 1.00 on a scale of −1 to +1 · 61 bars
RSI(14)
61.7
ADX(14)
27.7
Position in the price range
95%
Moving averages (daily)
Period
SMA
EMA
Price vs line
10 days
535.91
536.11
Above
20 days
520.64
527.90
Above
50 days
522.90
519.42
Above
100 days
508.99
506.67
Above
200 days
Indicators (daily)
Indicator
Value
Signal
RSI(14)
59.33
Up
MACD(12,26)
8.42
Up
ADX(14)
23.98
Neutral
ATR(14) % of price
1.80
Neutral
Support and resistance (weekly pivots)
s3490
s2504
s1
Trend score = average of the moving-average group and the indicator group ((up signals − down signals) ÷ number of signals) · RSI and ATR use Wilder's method · MACD uses the 12- and 26-period EMA · An ADX of 25 or above counts as a clear trend · Calculated from daily closing prices from Market data · Not investment advice
Capital Group New Economy Fund (LUX) – Class Z (USD)
N/A
1.66%
One fund counted per scheme · Funds investing through a master fund show the master fund's weight in VRTX, not the look-through weight · Past performance is not a guarantee of future performance
SCBIHEALT(SSFE)SCB Healthcare Innovation
LHHEALTH-A
DAOL-GIHEALTHDAOL GLOBAL INNOVATIVE HEALTHCARE FUND
TGHDIGITISCO Global Digital Health Equity Fund
UHCRMFUnited Global Healthcare RMF
ASP-IHEALTHAsset Plus Innovative Healthcare Fund
BCARERMFBualuang Global Health Care RMF
KASSET2